A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Clinical trial NCT00385827 · TERMINATED

Trial details

NCT number: NCT00385827
Sponsor: Centocor, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Cancer, Prostate

Start date: 2006-11-01
Primary completion: 2008-11-01
Enrollment: 106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.